What is the dose range for Milrinone administration?

What is the dose range for Milrinone administration?

• A. 0.1-0.5 mcg/kg/min
• B. 0.25-1 mcg/kg/min
• C. 1-2 mcg/kg/min
• D. 5-10 mcg/kg/min

Answer: (B)

Milrinone is a phosphodiesterase inhibitor primarily used in the management of heart failure, particularly in acute settings for patients who require inotropic support. The correct dosing range for Milrinone administration is between 0.25 and 1 mcg/kg/min. This dosing range is designed to provide optimal therapeutic effects while minimizing the risk of side effects. At this dosage, Milrinone enhances myocardial contractility and produces vasodilation, leading to improved cardiac output without excessively increasing myocardial oxygen demand. This is particularly important in the context of heart failure management, as it helps to balance the need for increased cardiac performance with the overall stability of the patient. Dosages below this range may not achieve the desired pharmacodynamics needed for effective treatment, while higher doses could lead to an increased risk of adverse effects, such as hypotension or arrhythmias. Therefore, the range of 0.25 to 1 mcg/kg/min is established based on clinical efficacy and safety profiles observed in patients receiving Milrinone therapy.

Milrinone is a phosphodiesterase inhibitor primarily used in the management of heart failure, particularly in acute settings for patients who require inotropic support. The correct dosing range for Milrinone administration is between 0.25 and 1 mcg/kg/min.

This dosing range is designed to provide optimal therapeutic effects while minimizing the risk of side effects. At this dosage, Milrinone enhances myocardial contractility and produces vasodilation, leading to improved cardiac output without excessively increasing myocardial oxygen demand. This is particularly important in the context of heart failure management, as it helps to balance the need for increased cardiac performance with the overall stability of the patient.

Dosages below this range may not achieve the desired pharmacodynamics needed for effective treatment, while higher doses could lead to an increased risk of adverse effects, such as hypotension or arrhythmias. Therefore, the range of 0.25 to 1 mcg/kg/min is established based on clinical efficacy and safety profiles observed in patients receiving Milrinone therapy.